AtaiBeckley (ATAI) Research & Development (2020 - 2026)
AtaiBeckley (ATAI) posted quarterly Research & Development of $17.4 million for Q1 2026, up 53.73% year-over-year from $11.3 million in Q1 2025, and up 53.73% quarter-over-quarter from $11.3 million in Q1 2025.
AtaiBeckley (ATAI) Research & Development (2020 - 2026) Analysis & Trends
AtaiBeckley has reported Research & Development for 6 years, with the latest figure at $14.7 million in Q3 2025.
- Quarterly Research & Development rose 18.61% year-over-year to $14.7 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $56.0 million (up 687.75% YoY) and the FY2024 annual result came in at $55.5 million, up 2672.75% from the prior year.
- Research & Development for Q1 2026 stood at $17.4 million, up from $11.3 million in the prior quarter.
- The five-year high for Research & Development was $17.4 million in Q1 2026, with the low at $11.3 million in Q1 2025.
- A 5-year average of $7.6 million and a median of $13.3 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2021 and 2022: Research & Development soared 461.53% in 2021, then plunged 482.35% in 2022.
- Over 5 years, Research & Development stood at $13.0 million in 2021, then slumped by 482.35% to -$49.6 million in 2022, then advanced by 7.23% to -$46.0 million in 2023, then jumped by 141.14% to $18.9 million in 2024, then declined by 22.5% to $14.7 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $14.7 million, $11.1 million, and $11.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | AtaiBeckley | 2.69 Bn | 2.69 Bn | - | 14.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.07 Mn |
| Mar 31, 2026 | 17.41 Mn |
| Sep 30, 2025 | 14.68 Mn |
| Jun 30, 2025 | 11.09 Mn |
| Mar 31, 2025 | 11.33 Mn |
| Mar 31, 2025 | 11.33 Mn |
| Dec 31, 2024 | 18.94 Mn |
| Sep 30, 2024 | 12.38 Mn |
| Jun 30, 2024 | 12.61 Mn |
| Mar 31, 2024 | 11.53 Mn |
| Dec 31, 2023 | -46.05 Mn |
| Sep 30, 2023 | 13.29 Mn |
| Jun 30, 2023 | 15.48 Mn |
| Mar 31, 2023 | 19.28 Mn |
| Dec 31, 2022 | -49.64 Mn |
| Sep 30, 2022 | 19.03 Mn |
| Jun 30, 2022 | 17.95 Mn |
| Mar 31, 2022 | 15.46 Mn |
| Dec 31, 2021 | 12.98 Mn |
| Sep 30, 2021 | 13.36 Mn |